Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Victor M Rivera

Showing results (71-80 of 95) with videos related to

Pageof 10
Sort By:
Chemical Biology & Drug Design|November 1, 2011
Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screenSen Zhang, Frank Wang, Jeffrey Keats, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 19, 2008
Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignanciesMonica M Mita, Alain C Mita, Quincy S Chu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2011
Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomasSant P Chawla, Arthur P Staddon, Laurence H Baker, et al.
The New England Journal of Medicine|November 30, 2012
Ponatinib in refractory Philadelphia chromosome-positive leukemiasJorge E Cortes, Hagop Kantarjian, Neil P Shah, et al.
The Lancet. Oncology|November 13, 2016
Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trialScott N Gettinger, Lyudmila A Bazhenova, Corey J Langer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2014
Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patientsAndrew P Garner, Joseph M Gozgit, Rana Anjum, et al.
Clinical Lung Cancer|June 29, 2025
Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non-Small-Cell Lung Cancer According to ALK Fusion and Mutation StatusLyudmila Bazhenova, J G Hodgson, D Ross Camidge, et al.
Blood|July 17, 2004
Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CMLThomas O'Hare, Roy Pollock, Eric P Stoffregen, et al.
Blood Cancer Journal|May 28, 2020
Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALLNicholas J Short, Hagop Kantarjian, Rashmi Kanagal-Shamanna, et al.
Blood|November 26, 2015
Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patientsMichael W Deininger, J Graeme Hodgson, Neil P Shah, et al.
Pageof 10

Showing results (71-80 of 95) with videos related to

Sort By:
Pageof 10
Chemical Biology & Drug Design|November 1, 2011
Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screenSen Zhang, Frank Wang, Jeffrey Keats, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 19, 2008
Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignanciesMonica M Mita, Alain C Mita, Quincy S Chu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2011
Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomasSant P Chawla, Arthur P Staddon, Laurence H Baker, et al.
The New England Journal of Medicine|November 30, 2012
Ponatinib in refractory Philadelphia chromosome-positive leukemiasJorge E Cortes, Hagop Kantarjian, Neil P Shah, et al.
The Lancet. Oncology|November 13, 2016
Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trialScott N Gettinger, Lyudmila A Bazhenova, Corey J Langer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2014
Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patientsAndrew P Garner, Joseph M Gozgit, Rana Anjum, et al.
Clinical Lung Cancer|June 29, 2025
Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non-Small-Cell Lung Cancer According to ALK Fusion and Mutation StatusLyudmila Bazhenova, J G Hodgson, D Ross Camidge, et al.
Blood|July 17, 2004
Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CMLThomas O'Hare, Roy Pollock, Eric P Stoffregen, et al.
Blood Cancer Journal|May 28, 2020
Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALLNicholas J Short, Hagop Kantarjian, Rashmi Kanagal-Shamanna, et al.
Blood|November 26, 2015
Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patientsMichael W Deininger, J Graeme Hodgson, Neil P Shah, et al.
Pageof 10